Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) differential diagnosis continues to be a challenge in neurology. This article details the recent MOGAD Masterclass in which 12 renewed experts from around the world discussed the diagnosis and management of the disease. This meeting was initiated funded and supported by UCB Biopharma SRL.
In this issue
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given